Gelsinger’s passing, back in 1999 sent the early stage of gene therapy into a 10 year funk in the US Almost overnight, an area with what seems to be a limitless medical commercial promise that was tainted.
Which is the reason to why what is happening currently might come off as surprising.
After a great amount time worrying and having doubts, gene therapy is in effect, utilizing genes as medicine is spreading across the hot biotech sector. Yet at the center of it all is none other than James Wilson.
Its is amazing turn of events for Wilson, who’s career was set off track more than a decade ago. Drug giants from Bayer AG to one of the brainchildren of Baxter International Inc. have followed scientific trails he has set on fire.
Venture capitalists are using hundreds of millions towards gene therapy start-ups, involving tow associated with Wilson. On the U.S. stock market, a dozen various gene therapy companies like Juno TherapeuticsInc., Bluebird Bio Inc. and Spark Therapeutics Inc Have a combined total of $20 billion
Wilson who is 60 years old states he is still shadowed by what happened to Gelsinger, whose mild form of the rare condition was posing no imminent danger of death when the trial initially began.